Should I Buy AMN? AMN 2026 Analysis

Should You Buy AMN Healthcare Services Inc (AMN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

20.190

1 Day change

-1.46%

52 Week Range

30.490

Analysis Updated At

2026/01/28

AMN is not a good buy right now for a beginner, long-term investor who is impatient on entry timing. The stock is technically overbought (RSI~81.7) and trading close to a key resistance zone (R1 ~21.96) while options volume is skewed bearish (put-heavy), suggesting limited near-term upside and higher risk of a pullback. I would hold off on initiating a new position at this level and reassess after a better entry or after the next earnings (2026-02-17).

Technical Analysis

Pre-market ~20.98 (+0.48%). Trend is currently bullish but stretched: MACD histogram is positive (0.454) yet contracting, implying upside momentum is slowing. RSI(6) at ~81.65 signals overbought conditions, which often precede consolidation or pullbacks. Moving averages are converging, suggesting the trend could pause rather than accelerate immediately. Key levels: pivot ~19.10 (important support/decision point); resistance R1 ~21.96 (nearby), then R2 ~23.72. With price already near resistance and RSI elevated, the risk/reward for an immediate entry is not attractive.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Open interest put/call of 0.45 is constructive (more calls than puts outstanding), which can indicate bullish positioning longer-term. However, the *option volume* put/call at 2.88 is strongly bearish for the day’s flow (puts dominating), implying near-term caution/hedging. Implied volatility is elevated (30D IV ~69.71 vs historical vol ~58.26) with IV percentile ~52, so options pricing is relatively expensive and the market is pricing meaningful swings. Net: longer-term positioning looks more positive than today’s sentiment, but the near-term tape is defensive.

Technical Summary

Sell

Buy

Positive Catalysts

Potential margin tailwind from a rebound in the international nurse business. Pattern-based forecast included in the data suggests positive skew over a month (+16.34% probability outcome), supporting a longer-term recovery thesis if the trend holds.

Neutral/Negative Catalysts

Technical setup is extended (RSI overbought) and price is approaching a key resistance level (~21.96), increasing odds of a near-term pullback. Options volume is put-skewed (bearish near-term sentiment). Latest quarter showed revenue decline and gross margin compression, indicating underlying demand/pricing pressure hasn’t fully normalized yet. Next earnings (2026-02-17 after hours) is a clear event risk with low implied EPS estimate (Est: 0.22), which can create volatility if guidance disappoints.

Financial Performance

Latest reported quarter: 2025/Q3. Revenue fell to ~$634.5M (-7.71% YoY), showing top-line contraction. Profitability improved sharply: Net income ~$29.3M (+319.06% YoY) and EPS $0.76 (+322.22% YoY), indicating meaningful cost/efficiency improvement and/or mix effects. However, gross margin declined to ~23.17 (-7.36% YoY), which suggests margin pressure remains in the core business even as bottom-line results improved. Overall: earnings rebound is encouraging, but the growth trend is mixed because revenue and gross margin are still down YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst actions are mixed but lean modestly constructive: Citizens JMP reiterated Outperform with a raised target to $24 (from $22) in Nov 2025; UBS maintained Neutral while raising target to $20.50 (from $18) in Nov 2025; Citizens later lowered its target to $22 (from $24) in Dec 2025 but kept Outperform, citing uneven near-term conditions and a better long-term staffing outlook. Wall Street pros: improving staffing demand trends and potential stabilization into 2026. Cons: near-term unevenness and ongoing margin pressure. Ownership/trading signals: hedge funds neutral and insiders neutral; no recent congress trading data available (no politician activity flagged).

7 Analyst Rating

Wall Street analysts forecast AMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMN is 21.5 USD with a low forecast of 20.5 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

3 Hold

1 Sell

Moderate Buy

Current: 20.490

Low

20.5

Averages

21.5

High

Current: 20.490

Low

20.5

Averages

21.5

High

Citizens

Outperform

maintain

$24 -> $22

AI Analysis

2025-12-19

Reason

Citizens

Price Target

$24 -> $22

AI Analysis

2025-12-19

maintain

Outperform

Reason

Citizens lowered the firm's price target on AMN Healthcare to $22 from $24 and keeps an Outperform rating on the shares. The firm's December Staffing Trends report updates provider contract labor spending, JOLTS data, nurse wage and exam trends, and reviews 2025 sector M&A activity, the analyst tells investors in a research note. While near-term conditions may remain uneven, the longer-term outlook for healthcare staffing is constructive, with potential for secular stabilization in 2026, the firm adds.

UBS

Neutral

maintain

$18

2025-11-07

Reason

UBS

Price Target

$18

2025-11-07

maintain

Neutral

Reason

UBS raised the firm's price target on AMN Healthcare to $20.50 from $18 and keeps a Neutral rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AMN

Unlock Now

AMN Should I Buy

AMN Should I Buy

Should You Buy AMN Healthcare Services Inc (AMN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch